SYRE vs. BBIO, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, PRGO, CRNX, and AXSM
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical preparations" industry.
BridgeBio Pharma (NASDAQ:BBIO) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership.
BridgeBio Pharma has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the S&P 500.
Spyre Therapeutics has a net margin of 0.00% compared to Spyre Therapeutics' net margin of -246.24%.
BridgeBio Pharma currently has a consensus price target of $47.62, indicating a potential upside of 69.99%. Spyre Therapeutics has a consensus price target of $43.17, indicating a potential upside of 23.51%. Given Spyre Therapeutics' higher possible upside, equities analysts clearly believe BridgeBio Pharma is more favorable than Spyre Therapeutics.
Spyre Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma received 133 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 68.25% of users gave BridgeBio Pharma an outperform vote.
99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 24.7% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, BridgeBio Pharma had 15 more articles in the media than Spyre Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 3 mentions for Spyre Therapeutics. BridgeBio Pharma's average media sentiment score of 0.94 beat Spyre Therapeutics' score of 0.44 indicating that Spyre Therapeutics is being referred to more favorably in the news media.
Summary
BridgeBio Pharma and Spyre Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
